The OMX Copenhagen 25 Index gained 1%, with Novo Nordisk A/S climbing 2.0% as the pharmaceutical firm said its semaglutide study showed benefits for liver treatment. CVS Health Corp.'s drug-benefits unit also negotiated a deal to make Novo's Wegovy more widely available to its members.
London's FTSE 100 edged lower, snapping its longest gaining streak since 2017, with a slate of disappointing earnings weighing on sentiment.
The export-heavy FTSE 100 fell 0.1% by 3.09pm in London. Lloyds Banking Group Plc dropped 1.8% as it missed earnings expectations and set aside more to prepare for a worsening economy.
